Blog Article
A strong MedTech investment thesis is only as executable as the leadership capability behind it.
Private equity investors are operating against a very different clock from most other owners.
An investment may have a four-to-seven-year hold period, but the value-creation plan cannot wait four to seven years to start working. Revenue growth, margin expansion, regulatory approvals, international expansion, acquisitions and operational improvements all have to happen within a defined window.
And the value-creation plan itself is usually highly specific.
Top-line growth might depend on increasing sales-force productivity, improving pricing, taking share within existing accounts, building direct commercial capability, entering new geographies, launching adjacent products or increasing recurring consumables and service revenue.
Margin improvement might depend on procurement, manufacturing productivity, organizational redesign, SG&A reduction, portfolio rationalization or footprint optimization.
Often, several of these things need to happen at the same time.
That makes leadership a particularly important part of the investment case.
The question is not simply whether a portfolio company has a strong management team. It is whether it has the right leadership capability for the specific value-creation plan and whether those leaders have demonstrated that capability in an environment that resembles the one they are being asked to lead.
In MedTech, that distinction matters even more. Experience is often highly specific to the product, regulatory pathway, market, company stage and commercial model.
A strong executive on paper is not necessarily the right executive for the next phase of the investment.
Here are seven leadership decisions PE investors should consider.
1. Assess management against the investment thesis, not generic leadership criteria
The starting point should be the investment thesis and its value-creation priorities, rather than a generic assessment of whether the management team looks impressive.
Suppose the thesis requires a €40 million company to become a €100 million business.
That tells us relatively little on its own.
Where is the additional €60 million actually expected to come from?
Is the plan to:
- increase sales productivity in an existing commercial organization?
- introduce greater pricing discipline?
- expand into the US or additional European markets?
- move from distributor-led selling to a direct model?
- increase penetration within existing hospital accounts?
- cross-sell additional products across the customer base?
- launch new products or indications?
- build recurring revenue from disposables, service or consumables?
- acquire and integrate complementary businesses?
Those are very different growth strategies and they require different leadership experience.
If margin expansion is equally important, the same principle applies.
Is the plan dependent on procurement savings, manufacturing efficiency, SG&A leverage, organizational restructuring, site consolidation or reducing product complexity?
Again, the relevant question is not whether the CEO, CFO, COO or CCO has an impressive CV.
It is whether they have personally delivered the particular combination of growth and margin improvement being underwritten.
Have they taken price without damaging volume?
Have they materially improved sales-force productivity?
Have they converted distributor markets to direct sales?
Have they integrated an acquisition and captured the expected commercial synergies?
Have they reduced COGS without compromising quality or regulatory compliance?
Have they grown revenue significantly faster than the underlying cost base and created genuine operating leverage?
This is where understanding the actual career history of an executive becomes important.
A title tells you very little on its own. What matters is what someone actually built, changed or delivered, at what stage of a company's development and under what commercial and regulatory conditions.
We saw this directly with Vernacare following its acquisition by H.I.G. Capital, where the requirement went well beyond filling a commercial leadership vacancy. The business needed to rebuild its commercial capability around the needs of the investment.
That requires a different approach to search: starting with the value-creation requirement and working backwards to the leadership experience needed to deliver it.
2. Prioritize executives who understand the PE environment
There is particular value in finding executives who have already operated successfully in private equity-backed businesses.
PE investors often have access to their own networks of executives and it is not unusual for proven operators to move from one sponsor-backed company to another. In some cases, investors will build teams around people who have successfully worked together before.
That experience is valuable because a PE-proven executive already understands the environment they are entering.
They understand that the business is operating against a defined value-creation plan.
They understand that growth has to translate into measurable enterprise value, not simply additional revenue.
They understand the difference between adding revenue and creating operating leverage.
A business that grows revenue 15% while EBITDA grows 5% may be getting bigger without becoming materially better. A business that grows revenue 15% while EBITDA grows 30% is demonstrating something very different.
That requires leaders who think simultaneously about:
Revenue → price → volume → mix → customer penetration → new customers → geographic expansion → acquisitions
Gross margin → pricing → procurement → manufacturing productivity → product mix
EBITDA → organizational productivity → SG&A leverage → operational efficiency
Cash → inventory → receivables → payables → capex discipline
PE-proven leaders are generally more accustomed to that level of accountability.
They understand the importance of hitting milestones rather than simply producing a long-term strategy. They are accustomed to board and investor scrutiny, faster decision-making, clear accountability and the need to translate operational progress into measurable value.
Just as importantly, they understand what it means to operate with a finite window in which to create that value.
Not every PE-backed company needs a management team made up exclusively of people who have worked in private equity, but PE experience is worth weighing as part of the assessment when the role calls for it, alongside the individual's sector, functional and stage-specific experience.
The strongest candidate may not have the biggest corporate pedigree.
They may simply be the person who has already delivered the particular transformation the investment requires.
3. Don't confuse corporate pedigree with PE capability
A senior executive from Medtronic, J&J MedTech, Stryker or another major strategic organization may be exceptional.
But running a large, established and well-resourced division is different from building a smaller PE-backed business from where it is today.
The skills can overlap, but they do not automatically transfer.
A corporate executive may have inherited:
- an established sales organization
- a recognized brand
- sophisticated marketing infrastructure
- mature regulatory teams
- established reimbursement
- global distribution
- central procurement
- well-developed systems
- large functional support teams.
A PE-backed MedTech business may instead need someone to create much of that capability.
They may need to restructure territories, replace weak commercial leadership, increase sales productivity, build key account management, renegotiate distributors, establish direct infrastructure in selected markets and introduce rigorous pricing discipline.
At the same time, they may be expected to simplify the organization, improve procurement, rationalize SG&A and increase EBITDA. That requires a different kind of executive.
PE-backed MedTech businesses often need leaders who are comfortable with incomplete infrastructure, limited resources, faster decision cycles and hands-on leadership.
They may need to build teams rather than inherit them, make decisions with imperfect information, work closely with the board and investors and adjust priorities as the investment case evolves.
The question therefore becomes:
Has this person operated successfully in an environment that actually resembles the one we are asking them to lead?
That is more useful than simply asking where they have worked.
It is also one that requires genuine market knowledge. Two executives can have almost identical titles and very different levels of relevant experience.
Knowing which is which comes from understanding what they actually did.
4. Match leadership to the next value-creation milestone
Leadership requirements change as a MedTech company moves through its investment cycle.
A company approaching FDA clearance needs different leadership from one that has just received approval and now needs to build a commercial organization.
A distributor-led business preparing to establish a direct sales model needs different capabilities from a business already operating at scale.
A business whose next major source of growth is pricing and account penetration needs different leadership from one entering ten new markets.
Likewise, a company whose investment case depends on EBITDA improvement through procurement and manufacturing optimization may need a very different operating team from one focused predominantly on top-line acceleration.
Relevant milestones might include:
- regulatory approval
- first commercial launch
- US market entry
- European expansion
- moving from distributor-led to direct sales
- building or restructuring a sales organization
- increasing pricing discipline
- improving sales-force productivity
- building recurring consumables or service revenue
- manufacturing scale-up
- acquisition integration
The practical question for the board or operating partner is: What does this company need to achieve over the next 24 to 36 months and which leaders have already navigated that transition?
VisionRT, which operates outside a traditional PE structure, provides a useful example of what that kind of transition demands. Its move towards a direct commercial model required leadership capability across multiple international markets rather than simply replacing one commercial executive.
The challenge was to build the organization needed for the next stage of the business. Filling a vacancy doesn't really capture that.
What it takes is identifying the leadership capability required by the next milestone in the value-creation plan.
5. Treat speed to milestone as a leadership issue
In PE, speed matters because time is part of the investment equation.
A delayed commercial launch, a missed regulatory milestone, a slow international expansion or an acquisition that takes too long to integrate can all reduce the time available to capture the value originally identified in the investment case.
The same is true of commercial underperformance.
If it takes twelve months to recognize that a sales organization is structurally ineffective, another six months to replace the leadership and another year for the new team to become fully productive, a meaningful portion of the investment period has disappeared.
Pricing provides another example. A management team that waits two years before addressing inconsistent discounting, poorly structured contracts or outdated price architecture has not simply missed some incremental margin.
It has lost two years of compounding EBITDA improvement. The cost of a leadership gap is therefore not limited to salary, recruitment fees or the cost of replacing an executive.
It can be the months of value-creation time lost while the problem is recognized, a replacement is identified and the new leader becomes effective.
The real objective is anticipating leadership requirements well before they become urgent, not simply “completing the search quickly.”
That means understanding the relevant talent pool, knowing which executives have already delivered the required milestone, maintaining relationships with potential candidates and, where appropriate, understanding which proven teams or operators might work together again.
Real market knowledge can make a meaningful difference here. For example, Guided Solutions filled 14 commercial roles for a PE-backed MedTech manufacturer across five months. What matters there isn't just the speed of the individual searches.
It is that a broader commercial requirement could be addressed because the wider requirement was understood from the outset rather than treated as a series of unrelated vacancies. Speed and rigor do not have to be competing objectives when the search begins with genuine knowledge of the talent market.
6. Build the management team for the next stage of ownership
A PE investor should not only ask whether the management team can deliver today's plan. It is worth asking what the leadership team needs to look like when the company reaches its next stage.
That might mean preparing for a strategic acquisition, a secondary buyout, another phase of sponsor ownership or, in some cases, a public-market environment.The requirements will change as the business grows.
A €40 million business can sometimes operate effectively with highly entrepreneurial leadership and relatively informal infrastructure.
A €150 million multinational MedTech business may require something very different:
- stronger financial controls
- more sophisticated revenue forecasting
- greater international leadership depth
- a more scalable commercial organization
- mature pricing and revenue management
- stronger supply-chain capability
- professionalized procurement
- greater regulatory depth
- improved data and systems
- additional functional expertise
- succession depth around key roles.
Acquisitions can accelerate that transition even further.
Buy-and-build strategies create their own leadership demands. Someone needs to determine what should genuinely be integrated, where commercial synergies exist, which products should be cross-sold, which distributors should be consolidated, where facilities overlap and which management structures are no longer required.
Buying revenue is relatively straightforward. Creating value from the acquired revenue is much harder.
That's less about swapping out executives the moment a company enters a new phase and more about recognizing that leadership requirements evolve and planning for that evolution rather than discovering it under exit pressure.
Nevro, which scaled under long-term strategic ownership rather than a PE fund before its eventual acquisition, illustrates this principle. As the company developed from a growth-stage business into a publicly listed organization, its leadership requirements changed with the scale and governance demands of the business.
The same principle applies within a PE investment. The team that is right for the beginning of the hold period is not automatically the team that will be right at the end of it.
7. Treat MedTech talent intelligence as part of value creation
The most useful relationship with a specialist search firm does not necessarily begin when an executive resigns. It can begin much earlier.
For a PE investor, knowing the MedTech leadership market can help answer questions such as:
- Which executives have actually delivered the type of growth in the investment thesis?
- Who has demonstrably improved pricing and commercial productivity?
- Who has taken a business successfully from distributor-led to direct?
- Which leaders have expanded internationally without allowing SG&A to grow at the same rate as revenue?
- Who has built high-performing MedTech sales organizations?
- Which executives have improved manufacturing margins or procurement?
- Who has successfully integrated acquisitions?
- Which operators have taken cost out of a business without damaging its capacity to grow?
- Which executives have successfully worked in PE-backed environments?
- Which leaders have already navigated the relevant regulatory or commercial milestone?
- Which proven operators or teams may be available for the next investment?
- What leadership capability will be needed before a role becomes live?
This is where specialist sector knowledge becomes more than a recruitment advantage.
A MedTech-focused partner should be able to provide insight into the people behind the titles: their track record, the environments in which they have operated, the organizations they have built, the milestones they have delivered and the circumstances in which they have been successful.
That includes understanding how they created value. That means separating genuine performance from favorable circumstance: whether revenue growth outpaced the market or simply rode it, whether margin expanded because pricing improved or because operations genuinely got better, whether the sales organization was built or inherited, and whether an acquisition created real commercial synergies or just added scale.
Those distinctions matter. They are particularly valuable when combined with access to executives who have already operated successfully in private equity. Because ultimately, the more useful question isn't:
"Who is available for this job?"
It is:
"Who has already created the kind of value our investment thesis requires, in an environment sufficiently similar to ours, and can they do it again?"
From investment thesis to leadership capability
For PE firms, value comes not from hiring impressive executives, but from putting the right leadership capability against the initiatives that underpin the investment thesis and doing so quickly enough for those leaders to make an impact within the investment cycle.
Those initiatives will vary considerably from investment to investment.
For one company, value creation may primarily mean accelerating revenue through pricing, sales-force productivity, customer penetration and geographic expansion.
For another, it may mean converting distributor markets to direct operations, launching new products and building recurring revenue.
For another, the greatest opportunity may be margin expansion through procurement, manufacturing productivity, organizational redesign, SG&A rationalization and footprint optimization. Usually, it is a combination. The ultimate objective is not simply growth or cost reduction in isolation.
It is to build a business that grows revenue while expanding gross margin, creating operating leverage, improving EBITDA and converting more of that EBITDA into cash. Leadership is the mechanism through which those plans get executed.
In MedTech, identifying that capability requires more than matching a title to a function.
It requires understanding what someone has actually done, the stage at which they did it, the scale of the business, the regulatory and commercial environment they operated in, whether they built the organization or inherited it, whether they have operated successfully under PE ownership and whether that experience genuinely transfers to the situation at hand.
That is the role Guided Solutions aims to occupy, going beyond recruiting MedTech executives to helping investors understand the MedTech leadership market and identify the people capable of delivering the investment thesis.
If you are underwriting, reviewing or executing a MedTech investment thesis, the first question may not be who you need to hire. It may be whether the leadership capability you need already exists in the business and, if it does not, where in the market it can be found.
